Rheumatoid arthritis, Periodontitis
Conditions
Interventions
IL-6 receptor inhibition group: Tocilizumab will be infused in 20 patients, and its effectiveness will be evaluated at 3 and 6 months later.
TNF inhibition group: Infliximab, Etanercept, and Adal
Sponsors
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals whose consents are obtained in written form on participation in the present study. 2. Individuals with rheumatoid arthritis who have a minimum of 20 teeth.
Exclusion criteria
Exclusion criteria: 1.Individuals who had received scaling and root planing within the previous 3 months before the study starts. 2.Individuals who had taken systemic antibiotics or anti-inflammatory drugs within 3 months before the study starts. 3.Individuals with severe systemic diseases 4.Individuals who are or suspected to be pregnant. 5.Individuals who are considered not eligible for the present study due to any reasons by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gingival index Bleeding on probing Probing pocket depth Clinical attachment level | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum markers hsCRP IL-6 TNF-alpha MMP-3 | — |
Countries
Japan
Contacts
Public ContactTetsuo Kobayashi
Niigata University Medical and Dental Hospital General Dentistry and Clinical Education Unit
Outcome results
None listed